Chagas Disease Chemotherapy: What Do We Know So Far?

Area of Science:

• Parasitology
• Infectious Diseases
• Drug Discovery

Background:

• Chagas disease affects millions globally and is classified as a Neglected Tropical Disease (NTD).
• Current treatments, benznidazole (BZ) and nifurtimox, are ineffective in the chronic phase and cause side effects.
• BZ cure rates drop significantly from 80% in the acute phase to 20% in chronic phase adults.

Purpose of the Study:

• To review recent studies on antiparasitic drug potential for Chagas disease.
• To identify novel compounds, drug repositioning, and combination therapies.
• To evaluate drugs with potential superiority or equivalency to BZ.

Main Methods:

• Review of scientific literature published in the last six years.
• Analysis of studies on synthesized compounds, drug repositioning, and combination therapies.
• Evaluation of in vitro and in vivo antiparasitic activity.

Main Results:

• Several compounds demonstrated antiparasitic activity comparable or superior to BZ.
• Identified potential new therapeutic agents for Chagas disease.
• Highlighted variability in BZ efficacy due to methodological differences.

Conclusions:

• Further in vitro and in vivo studies are warranted for promising compounds.
• Standardization of experimental methods is crucial for comparing drug efficacy.
• Development of improved treatments for Chagas disease remains a critical need.